Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s Disease Treated with Donepezil.

This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth.

Potential patients must have been receiving a drug containing Donepezil for the last 6 months,

The post Mild to Moderate Alzheimer’s Disease Treated with Donepezil appeared first on Palm Beach Neurological Center.